German biotech AquaNab, developing alpaca-derived nanoantibody technology for aquaculture, has secured funding to accelerate the development of its platform.
Data on the amount of lice on migrating young salmon, sea trout and sea char contributes to the decision-making process as part of the country's "traffic light" system for aquaculture regulation.
The research on the proteins identified in the secretory and excretory products (SEPs) of the infectious copepodid stage of the salmon louse is funded by EastBio.
Fresh backing from aquaculture investors including Grieg Kapital and Hatch Blue will fund the commercial rollout of the company’s individual-based sea lice removal system.